Ivan Hyep sold $553k of BCAX
Chief Financial Officer at Bicara Therapeutics Inc.. 30,385 shares at an average of $18.21, traded Oct 6, 2025, filed Oct 8, 2025.
Score components
- +22RoleCFO
- +19Trade size$553k at market
- +5Share of holdings soldSold 20% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -18.7%, 3m -4.6%, 6m +20.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002034668-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 6, 2025 | MOption exercise Common Stock10b5-1 | +6,514 | $3.79 | $25k | 151,869 | Oct 8, 2025 |
| Oct 6, 2025 | SOpen-market sale Common Stock10b5-1 | -6,514 | $18.17 | $118k | 145,355 | Oct 8, 2025 |
| Oct 7, 2025 | MOption exercise Common Stock10b5-1 | +18,244 | $3.79 | $69k | 163,599 | Oct 8, 2025 |
| Oct 7, 2025 | SOpen-market sale Common Stock10b5-1 | -18,244 | $18.22 | $332k | 145,355 | Oct 8, 2025 |
| Oct 8, 2025 | MOption exercise Common Stock10b5-1 | +5,627 | $3.79 | $21k | 150,982 | Oct 8, 2025 |
| Oct 8, 2025 | SOpen-market sale Common Stock10b5-1 | -5,627 | $18.21 | $102k | 145,355 | Oct 8, 2025 |
| Oct 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,514 | $0.00 | $0 | 146,870 | Oct 8, 2025 |
| Oct 7, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,244 | $0.00 | $0 | 128,626 | Oct 8, 2025 |
| Oct 8, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,627 | $0.00 | $0 | 122,999 | Oct 8, 2025 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 18Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $525k 18,750 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $280k 10,000 shares | -3% | |
| 17Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $350k 12,500 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $284k 10,000 shares | -3% | |
| 29Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $808k 28,000 shares | -18% | |
| 28Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $833k 28,750 shares | -14% | |
| 14Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $188k 9,200 shares | -6% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $301k 15,000 shares | -4% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $254k 12,500 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.